PTGS2 and colorectal carcinoma: Although several prior clinical trials testing SRC or COX2 inhibitors in patients with CRC have failed to show meaningful clinical activity48–53, no trial has yet focused on BRAFV600E mCRC or evaluated these agents in combination with BRAF-targeted therapies.